Cetero sold to investor group, renamed PRACS Institute

Wednesday, June 20, 2012 02:38 PM

Cary, N.C.-based Cetero Research has finalized the sale of the company to its investor group, led by Freeport Financial, following the company’s Chapter 11 bankruptcy filing court approval of the sale.

As part of the new ownership structure, the company’s headquarters will move to Fargo, N.D., and the company has been renamed PRACS Institute.

The board of directors has named three executive appointments to lead operational, financial and new business initiatives. James Carlson, Pharm.D, has been named CEO. Carlson has more than 30 years of experience in early phase research. He co-founded and served as CEO of Cetero Research, based in Fargo, N.D., from 1983 to 2006, where he oversaw the conduct of more than 450 studies per year across a range of therapeutic indications and study types.

Mark Ubert, CPA, MBA, has been named CFO. Ubert joined Cetero in 2009 as corporate controller. John Pottier has been named executive vice president, business development. Joining PRACS from Worldwide Clinical Trials, Pottier previously served in business development roles at Novum Research, Cetero Research and PRACS Institute, after beginning his career at the Clinical Research Foundation, now part of Quintiles Transnational.

Founded in 2004 by a group of corporate finance and capital markets professionals, Freeport Financial provides capital and leveraged finance solutions to middle market companies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs